Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...
Be part of the 84TH EAS Congress (EAS 2016) and gain access to an outstanding scientific programme focused on the latest topics and discoveries in the field of atherosclerotic disease. With unique ...
Evidence for Vitamins and Nutrition in Cardiovascular Disease? EAS 2007: The goal of using diet and dietary supplements to treat cardiovascular risk and disease continues to motivate serious study -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback